Odyralduo (Dorzolamide, Timolol)

Dorzolamide inhibits the enzyme carbonic anhydrase in the ciliary body of the eye. This inhibition reduces the production of aqueous humor, the fluid that maintains intra‑ocular pressure. When paired with timolol, which blocks beta‑adrenergic receptors, the overall effect is a significant decrease in eye pressure.

The dosing regimen for Odyralduo is determined by the prescribing ophthalmologist based on the patient’s condition, response, and tolerance. Typically, one drop is instilled in the affected eye(s) once or twice daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for dorzolamide and timolol during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Odyralduo combines two mechanisms—carbonic anhydrase inhibition and beta‑blockade—into a single formulation, offering greater pressure‑lowering efficacy than many single‑agent drops. Compared with prostaglandin analogues, it may have a different side‑effect profile, such as less eyelash growth but more ocular irritation. Choice of therapy depends on individual patient factors and physician judgment.

Odyralduo should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light, and avoid exposure to moisture. Do not freeze the solution. If the product appears discolored or contains particles, discard it.

Odyralduo is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and instill the prescribed number of drops without touching the tip of the bottle to the eye or any surface. Close the eye gently after administration.

Serious risks include severe allergic reactions (e.g., angio‑edema, anaphylaxis), marked bradycardia or heart block, bronchospasm in patients with reactive airway disease, and systemic hypotension. Patients should be instructed to seek immediate medical attention if they experience symptoms such as difficulty breathing, rapid weight gain, swelling, or fainting.

Odyralduo is contraindicated in patients with known hypersensitivity to dorzolamide, timolol, sulfonamides, or any component of the formulation. It should also be avoided in individuals with severe sinus bradycardia, second‑ or third‑degree heart block, uncontrolled asthma, or chronic obstructive pulmonary disease without medical supervision.